IMAPAC Glossary

A multiplex assay is an analytical method that simultaneously measures multiple biological targets within a single sample.

A multivalent vaccine protects against multiple strains, serotypes or pathogens by incorporating more than one antigen into a single formulation.

A mutation is a permanent alteration in the DNA sequence that may affect gene function, protein expression or disease development.

Mutation burden assessment measures the number of genetic mutations within a tumour or genome to support disease characterisation and treatment selection.

Mycoplasma are small bacteria lacking a cell wall that commonly contaminate cell cultures and compromise research and biopharmaceutical manufacturing.

A nanocarrier is a nanoscale delivery system designed to transport therapeutic agents while improving targeting, stability and controlled release.

Nanomedicine applies nanotechnology to the diagnosis, prevention and treatment of disease using nanoscale materials and delivery systems.

A nanoparticle is a microscopic particle typically measuring between 1 and 100 nanometres that is used for drug delivery, imaging and therapeutic applications.

A Natural Killer (NK) cell is an innate immune cell that destroys infected or cancerous cells without prior antigen sensitisation.

Nearest neighbour imputation estimates missing data values by using observations with the most similar characteristics within a dataset.

Necrosis is uncontrolled cell death resulting from severe injury, leading to membrane rupture and inflammation of surrounding tissues.

A neoantigen is a newly formed antigen produced by tumour-specific mutations that can be recognised by the immune system.

Nephrotoxicity risk stratification categorises patients according to their likelihood of developing kidney injury associated with therapeutic products.

Network meta-analysis integrates evidence from multiple clinical studies to compare several treatments simultaneously, including those not directly compared.

A neuromuscular adverse effect is an unwanted treatment-related effect involving muscles, peripheral nerves or neuromuscular transmission.

A neurotoxicity screening battery comprises validated tests used to detect adverse effects of therapeutic products on the nervous system.

A neutralising antibody is an antibody that blocks the biological activity or infectivity of a pathogen, toxin or therapeutic target.

The neutrophil-to-lymphocyte ratio (NLR) is an inflammatory biomarker calculated from blood cell counts to assess disease severity, prognosis or treatment response.

A New Drug Application (NDA) is a regulatory submission requesting approval to market a new medicinal product based on evidence of safety, efficacy and quality.

Non-compartmental analysis is a model-independent pharmacokinetic approach used to estimate exposure, clearance and other pharmacokinetic parameters from concentration-time data.

A nonsense mutation is a genetic alteration that introduces a premature stop codon, producing a truncated and usually non-functional protein.

A novel excipient regulatory pathway defines the regulatory requirements for evaluating the safety and approval of previously unapproved pharmaceutical excipients.

A nucleic acid is a biological macromolecule, including DNA and RNA, that stores, transmits and regulates genetic information.

Nucleic acid sequencing technology determines the order of nucleotides within DNA or RNA to support research, diagnostics and precision medicine.

Nucleotide synthesis inhibition blocks the production of nucleotides required for DNA and RNA synthesis, limiting cell proliferation or viral replication.

An occupational exposure limit defines the maximum acceptable concentration of a hazardous substance to protect workers during routine occupational exposure.

Oligonucleotide therapy uses short synthetic DNA or RNA molecules to modify gene expression or protein production for therapeutic purposes.

An oncogene is a gene that promotes uncontrolled cell growth and contributes to cancer development when activated or overexpressed.

Oncogene amplification detection identifies increases in oncogene copy number that contribute to cancer development and guide targeted treatment decisions.

An oncolytic virus is a naturally occurring or engineered virus that selectively infects and destroys cancer cells while stimulating anti-tumour immune responses.

Opsonisation is the immune process in which pathogens or particles are coated with opsonins to enhance their recognition and destruction by phagocytic cells.

Oral bioavailability enhancement uses formulation or delivery strategies to increase the proportion of an orally administered drug reaching systemic circulation.

An organoid is a three-dimensional cellular structure grown in vitro that replicates key structural and functional features of human organs.

Organometal compound toxicity evaluates the harmful biological effects associated with compounds containing metal-carbon chemical bonds.

An orphan drug is a medicinal product developed specifically to treat rare diseases affecting relatively small patient populations.

Orphan drug designation provides regulatory incentives for developing medicines intended to treat rare diseases affecting small patient populations.

Orthogonal testing uses multiple independent analytical methods to evaluate the same quality attribute, increasing confidence in analytical results.

Osmolality is the concentration of osmotically active particles in a solution, influencing cell function and pharmaceutical formulation performance.

The osmotic stress response comprises cellular mechanisms that maintain homeostasis when exposed to changes in osmotic pressure.

An osteoclast is a specialised bone-resorbing cell responsible for breaking down bone tissue during normal skeletal remodelling.

Osteoclast inhibition strategies reduce bone resorption by suppressing osteoclast formation or activity to preserve bone strength and integrity.

Osteogenesis is the biological process of bone formation through the differentiation and activity of specialised bone-forming cells.

Ototoxicity risk assessment evaluates the likelihood that a therapeutic product may damage hearing or balance function.

Out-of-Specification (OOS) refers to analytical test results that fall outside predefined acceptance criteria for pharmaceutical materials or products.

Outpatient safety monitoring systematically evaluates patients receiving treatment outside hospital settings to detect adverse events and ensure safe therapy.

An overexpression system is an engineered biological platform designed to produce high levels of a specific protein for research or manufacturing purposes.

Oxidation is a chemical process involving electron loss that can alter the stability, structure or activity of pharmaceutical compounds and biologics.

Oxidative stress is a biological condition in which reactive oxygen species exceed antioxidant defences, leading to cellular damage.

An oxidative stress biomarker is a measurable indicator of cellular damage or antioxidant status resulting from excessive reactive oxygen species.

Oxygenation is the process of supplying oxygen to cells, tissues or biological systems to support aerobic metabolism and cell viability.

A pangenome is the complete collection of genes found across all strains or individuals within a species.

Parenteral describes the administration of medicines by routes that bypass the gastrointestinal tract, such as intravenous, intramuscular or subcutaneous injection.

Particle size distribution measures the range and proportion of particle sizes within a sample, affecting product quality, stability and manufacturing performance.

Partition coefficient optimisation adjusts the lipophilicity of a compound to improve absorption, tissue distribution, formulation performance and overall pharmacokinetic properties.

Passive immunisation provides immediate but temporary protection by administering preformed antibodies rather than stimulating the body's own immune response.

A Pathogen-Associated Molecular Pattern (PAMP) is a conserved microbial molecule recognised by the innate immune system to initiate immune responses.

Pathogenicity assessment evaluates the ability of a microorganism or biological agent to cause disease and the severity of its effects.

Pathway enrichment analysis is a bioinformatics method that identifies biological pathways significantly associated with a set of genes or proteins.

A Patient-Derived Xenograft (PDX) is a preclinical model created by implanting human tumour tissue into immunodeficient animals for cancer research.

Patient stratification is the process of grouping patients according to biological, clinical or genetic characteristics to optimise treatment selection.

A peptide is a short chain of amino acids linked by peptide bonds that performs structural, signalling or therapeutic functions.

A peptidomimetic is a compound designed to mimic the biological activity of a peptide while improving stability or pharmacological properties.

Permeability is the ability of a molecule to cross biological membranes, influencing its absorption, distribution and overall effectiveness as a therapeutic product.

Personalised medicine is an approach that tailors disease prevention or treatment according to an individual's genetic, molecular or clinical characteristics.

P-glycoprotein is a membrane transport protein that pumps drugs and other compounds out of cells, influencing drug absorption and resistance.

Phage display is a laboratory technique that uses bacteriophages to display peptides or proteins for selecting molecules with specific binding properties.

A pharmacodynamic biomarker is a measurable biological indicator that demonstrates a therapeutic product's biological activity or pharmacological effect.

Pharmacodynamics (PD) is the study of the biochemical, physiological and molecular effects of drugs and the relationship between drug concentration and therapeutic response.

Pharmacogenetics examines how inherited genetic variations influence individual responses to medicines, supporting the development of more personalised treatment strategies.

The pharmacokinetic-pharmacodynamic relationship describes how drug exposure influences the onset, magnitude and duration of therapeutic or biological effects.

Pharmacokinetics (PK) is the study of how the body absorbs, distributes, metabolises and eliminates a drug over time.

Pharmacometrics uses mathematical modelling and simulation to integrate pharmacokinetic, pharmacodynamic and clinical data to optimise drug development and dosing strategies.

A pharmacophore is the three-dimensional arrangement of molecular features required for a compound to bind its biological target and produce a therapeutic effect.

Pharmacovigilance is the systematic process of detecting, assessing, understanding and preventing adverse drug reactions and other medicine-related safety issues.

Pharmacovigilance plan implementation establishes the processes, responsibilities and activities required to continuously monitor, evaluate and manage the safety of a medicinal product after approval.

Phase I clinical trials are the first studies of investigational therapies in humans, primarily assessing safety, tolerability and pharmacokinetics.

Phase II clinical trials evaluate the efficacy, safety and optimal dosing of investigational therapies in patients with the target disease.

Phase III clinical trials confirm the efficacy and safety of investigational therapies by comparing them with existing treatments or placebos in large patient populations.

Phase IV studies are post-marketing clinical investigations that monitor the long-term safety, effectiveness and real-world use of approved therapies.

Phenotype refers to the observable characteristics of an organism resulting from interactions between its genetic makeup and environmental influences.

Phosphorylation is the enzymatic addition of phosphate groups to proteins or other molecules, regulating cellular signalling and biological activity.

A placebo is an inactive substance or sham treatment used as a control in clinical trials to evaluate the true effects of investigational therapies.

Plasma protein binding describes the reversible interaction between therapeutic compounds and plasma proteins, influencing distribution, clearance and pharmacological activity.

A plasmid is a small circular DNA molecule that exists independently of chromosomal DNA and is widely used in molecular biology and recombinant protein production.

A pluripotent stem cell is a stem cell capable of differentiating into nearly all specialised cell types found within the human body.

Polymerase Chain Reaction (PCR) is a molecular biology technique that amplifies specific DNA sequences, enabling their rapid detection and analysis.

Polypharmacy complexity management addresses the risks associated with multiple concurrent medicines by optimising treatment regimens, monitoring interactions and improving patient safety.

Post-translational modifications are chemical changes made to proteins after synthesis that influence their structure, function, stability and biological activity.

Pregnancy category classification categorises medicines according to available evidence on their potential risks and safety during pregnancy.

A prodrug is an inactive or less active compound that is converted into its active therapeutic form through metabolic or chemical processes in the body.

A protease is an enzyme that catalyses the breakdown of proteins by cleaving peptide bonds, supporting numerous biological and physiological processes.

A protease inhibitor is a therapeutic agent that blocks the activity of protease enzymes to prevent disease-related biological processes.

Qualification is the documented process demonstrating that equipment, facilities, systems or utilities perform as intended for their intended use.

A Qualified Person (QP) is an authorised individual responsible for certifying that medicinal products comply with regulatory and manufacturing requirements before release.

A quality agreement is a formal document defining the quality responsibilities and obligations between organisations involved in pharmaceutical manufacturing or testing.

Quality Assurance (QA) comprises systematic activities that ensure pharmaceutical products and processes consistently meet predefined quality standards.

A quality attribute is a measurable physical, chemical, biological or microbiological characteristic used to assess the quality of a pharmaceutical product.

A quality attribute hierarchy organises critical and supporting quality attributes according to their impact on product quality, safety and therapeutic performance.

Quality by Design (QbD) is a science-based approach to pharmaceutical development that builds product quality into processes through systematic understanding and risk management.

Quality Control (QC) consists of testing and inspection activities that verify materials, products and processes comply with established quality specifications.